Once-a-day administration of everolimus is safe in de novo renal transplant recipients: 1-year results of a pilot study
Academic Article
Publication Date:
2011
Short description:
Spagnoletti, G., Favi, E., Gargiulo, A., Salerno, M. P., Citterio, F., Once-a-day administration of everolimus is safe in de novo renal transplant recipients: 1-year results of a pilot study, <>, 2011; 43 (4): 1010-1012. [doi:10.1016/j.transproceed.2011.03.018] [http://hdl.handle.net/10807/52178]
abstract:
The half-life of everolimus is approximately 28 hours, but everolimus is generally administered twice a day. The aim of this prospective, single-center, exploratory study was to compare the efficacy and safety of a once a day everolimus (OD) with the standard twice a day administration regimen (BID) as immunosuppressive therapy in renal transplantation.
Iris type:
Articolo in rivista, Nota a sentenza
Keywords:
Kidney Transplantation; Administration, Oral; Antibodies, Monoclonal; Calcineurin; Chi-Square Distribution; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Italy; Male; Pilot Projects; Prospective Studies; Recombinant Fusion Proteins; Risk Assessment; Risk Factors; Sirolimus; Time Factors; Treatment Outcome
List of contributors:
Spagnoletti, Gionata; Favi, E; Gargiulo, A; Salerno, Maria Paola; Citterio, Franco
Published in: